» Articles » PMID: 38233595

Inherited Polygenic Effects on Common Hematological Traits Influence Clonal Selection on JAK2 and the Development of Myeloproliferative Neoplasms

Abstract

Myeloproliferative neoplasms (MPNs) are chronic cancers characterized by overproduction of mature blood cells. Their causative somatic mutations, for example, JAK2, are common in the population, yet only a minority of carriers develop MPN. Here we show that the inherited polygenic loci that underlie common hematological traits influence JAK2 clonal expansion. We identify polygenic risk scores (PGSs) for monocyte count and plateletcrit as new risk factors for JAK2 positivity. PGSs for several hematological traits influenced the risk of different MPN subtypes, with low PGSs for two platelet traits also showing protective effects in JAK2 carriers, making them two to three times less likely to have essential thrombocythemia than carriers with high PGSs. We observed that extreme hematological PGSs may contribute to an MPN diagnosis in the absence of somatic driver mutations. Our study showcases how polygenic backgrounds underlying common hematological traits influence both clonal selection on somatic mutations and the subsequent phenotype of cancer.

Citing Articles

JAK2-V617F mutation among blood donors: A meta-analysis.

Alsharif M, Mansory E, Alharazi A, Badawi M Saudi Med J. 2024; 45(12):1289-1304.

PMID: 39658117 PMC: 11629640. DOI: 10.15537/smj.2024.45.12.20240594.


Molecular profiling in MPN: who should have it and why?.

Chee A, Mead A Hematology Am Soc Hematol Educ Program. 2024; 2024(1):524-534.

PMID: 39644028 PMC: 11665577. DOI: 10.1182/hematology.2024000576.


Myeloproliferative Neoplasms: Challenging Dogma.

Spivak J J Clin Med. 2024; 13(22).

PMID: 39598101 PMC: 11595126. DOI: 10.3390/jcm13226957.


PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.

Saber S, Abdelhady R, Elhemely M, Elmorsy E, Hamad R, Abdel-Reheim M Front Pharmacol. 2024; 15:1475998.

PMID: 39564119 PMC: 11573589. DOI: 10.3389/fphar.2024.1475998.


Germline determinants of aberrant signaling pathways in cancer.

Dalfovo D, Scandino R, Paoli M, Valentini S, Romanel A NPJ Precis Oncol. 2024; 8(1):57.

PMID: 38429380 PMC: 10907629. DOI: 10.1038/s41698-024-00546-5.

References
1.
Nangalia J, Green A . Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017; 130(23):2475-2483. DOI: 10.1182/blood-2017-06-782037. View

2.
Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

3.
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman P, Mar B . Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-98. PMC: 4306669. DOI: 10.1056/NEJMoa1408617. View

4.
McKerrell T, Park N, Moreno T, Grove C, Ponstingl H, Stephens J . Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015; 10(8):1239-45. PMC: 4542313. DOI: 10.1016/j.celrep.2015.02.005. View

5.
Nielsen C, Bojesen S, Nordestgaard B, Kofoed K, Birgens H . JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica. 2014; 99(9):1448-55. PMC: 4562533. DOI: 10.3324/haematol.2014.107631. View